$0.53
10.88% yesterday
Nasdaq, Nov 25, 09:47 pm CET
ISIN
US68404V1008
Symbol
OPTN

OptiNose, Inc. Stock price

$0.53
-0.24 31.35% 1M
-0.58 52.29% 6M
-0.76 58.95% YTD
-0.67 55.87% 1Y
-1.16 68.66% 3Y
-9.20 94.56% 5Y
-18.47 97.21% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.05 10.33%
ISIN
US68404V1008
Symbol
OPTN
Sector

Key metrics

Market capitalization $79.88m
Enterprise Value $124.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.64
P/S ratio (TTM) P/S ratio 1.06
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 5.13%
Revenue (TTM) Revenue $75.67m
EBIT (operating result TTM) EBIT $-19.19m
Free Cash Flow (TTM) Free Cash Flow $-39.79m
Cash position $82.50m
EPS (TTM) EPS $-0.28
P/E forward negative
P/S forward 1.01
EV/Sales forward 1.58
Short interest 7.22%
Show more

Is OptiNose, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

OptiNose, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a OptiNose, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a OptiNose, Inc. forecast:

Buy
100%

Financial data from OptiNose, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
76 76
5% 5%
100%
- Direct Costs 7.76 7.76
19% 19%
10%
68 68
9% 9%
90%
- Selling and Administrative Expenses 82 82
1% 1%
109%
- Research and Development Expense 4.37 4.37
37% 37%
6%
-19 -19
33% 33%
-25%
- Depreciation and Amortization 0.35 0.35
15% 15%
0%
EBIT (Operating Income) EBIT -19 -19
33% 33%
-25%
Net Profit -31 -31
23% 23%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about OptiNose, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OptiNose, Inc. Stock News

Neutral
Seeking Alpha
14 days ago
OptiNose, Inc. (NASDAQ:OPTN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jonathan Neely - Vice President of Investor Relations and Business Development Ramy Mahmoud - Chief Executive Officer Terry Kohler - Chief Financial Officer Paul Spence - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets David Amsellem ...
Neutral
GlobeNewsWire
14 days ago
Company reports Q3 2024 XHANCE net revenue of $20.4 million , an increase of 3% compared to Q3 2023
Neutral
GlobeNewsWire
21 days ago
Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time
More OptiNose, Inc. News

Company Profile

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Head office United States
CEO Ramy Mahmoud
Employees 132
Founded 2000
Website www.optinose.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today